Syndax Soars 9.1% on FDA Expansion and NCCN Inclusion – What’s Next for Biotech’s Rising Star?

Summary
• Syndax Pharmaceuticals (SNDX) surges 9.1% intraday, hitting a 52-week high of $19.56
• Q3 revenue jumps 21% to $45.9M, driven by Revuforj’s 25% prescription growth
• FDA approves Revuforj for expanded AML use; NCCN guidelines now include the therapy

Biotech stocks are in a frenzy as Syndax Pharmaceuticals (SNDX) rockets 9.1% in post-market trading, fueled by regulatory milestones and robust revenue growth. The stock’s intraday high of $19.56 matches its 52-week peak, signaling a pivotal moment for the oncology-focused firm. With Revuforj’s expanded FDA approval and inclusion in NCCN guidelines, investors are recalibrating their expectations for Syndax’s commercial potential.

Regulatory Wins and Revenue Surge Drive SNDX’s Bullish Breakout
Syndax’s 9.1% surge is anchored by two landmark events: the FDA’s October 24 approval of Revuforj for relapsed/refractory NPM1-mutated AML in both adults and pediatric patients, and the inclusion of Revuforj in the NCCN Clinical Practice Guidelines for AML. These developments validate Syndax’s leadership in menin inhibition and position Revuforj as a first-line therapy for a broader patient population. Concurrently, Q3 revenue of $45.9 million—up 21% from Q2—underscores Revuforj’s commercial traction, with prescriptions rising 25% quarter-over-quarter. The stock’s breakout above key resistance levels aligns with these catalysts, amplifying investor optimism.

Pharma Sector Volatility Amid Mixed Biotech News
The broader pharmaceutical sector remains volatile, with peers like Novo Nordisk and Merck navigating mixed trial outcomes and regulatory scrutiny. However, Syndax’s rally is distinct, driven by its precision oncology focus and Revuforj’s unique positioning in AML treatment. While sector leader Johnson & Johnson (JNJ) edged up 0.4%, Syndax’s performance highlights the sector’s bifurcation between established players and high-growth biotechs with clear regulatory milestones.

Options and ETFs to Capitalize on SNDX’s Momentum
• RSI: 72.55 (overbought), MACD: 0.64 (bullish), 200D MA: $13.10 (well below price)
• Bullish Engulfing Candlestick Pattern confirmed, with RSI nearing overbought territory and MACD above signal line

Top Options Contracts:
• SNDX20251219C20 (Call, $20 strike, 12/19 expiry):
- IV: 96.40% (high volatility)
- LVR: 10.83% (moderate leverage)
- Delta: 0.516 (moderate sensitivity)
- Theta: -0.051 (rapid time decay)
- Gamma: 0.079 (responsive to price swings)
- Turnover: $35.5M (liquid)
- Payoff at 5% upside: $0.98/share (125% gain)
- Why it stands out: High IV and gamma make this call ideal for a short-term rally, with liquidity ensuring smooth entry/exit.
• SNDX20251219C21 (Call, $21 strike, 12/19 expiry):
- IV: 82.98% (moderate volatility)
- LVR: 16.95% (strong leverage)
- Delta: 0.416 (balanced sensitivity)
- Theta: -0.043 (moderate decay)
- Gamma: 0.090 (high responsiveness)
- Turnover: $68.5M (high liquidity)
- Payoff at 5% upside: $0.98/share (96% gain)
- Why it stands out: Combines moderate IV with high gamma and leverage, offering a balanced risk-reward profile for a continued bullish move.

Action Plan: Aggressive bulls should target SNDX20251219C20 for a 5% upside play, while SNDX20251219C21 offers a safer, leveraged entry. Key support at $15.57 and resistance at $19.56 define the near-term range. Watch for a break above $19.56 to confirm a multi-week uptrend.

Backtest Syndax Stock Performance
Below is the interactive back-test report. Please open the module to review the full performance statistics and trades.Notes on auto-filled settings • Stop-loss (15 %) / Take-profit (120 %) / Max Hold Days (30) are common risk-control defaults for momentum tests when the user does not specify exit rules. • Price series uses daily closes from 2022-01-01 to 2025-11-23 (latest available). Let me know if you’d like to adjust any parameters or explore deeper analytics.

Syndax’s Breakout: A Catalyst-Driven Rally with Clear Pathways
Syndax’s 9.1% surge is a masterclass in regulatory and commercial momentum, with Revuforj’s FDA expansion and NCCN inclusion acting as dual catalysts. The stock’s technicals—overbought RSI, bullish MACD, and a key breakout—signal a high-probability continuation of the rally. Investors should monitor the $19.56 level for a potential push toward $21, while sector leader Johnson & Johnson’s 0.4% gain suggests broader market support. For those seeking leverage, SNDX20251219C20 and C21 offer compelling options. Act now: Buy SNDX20251219C21 for a leveraged play on the next leg up, targeting $21.50 by December 19.